Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivabradine + metoprolol (Servier)
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Implicor is an oral fixed-dose combination (FDC) therapy containing ivabradine hydrochloride and metoprolol tartrate. Developed by Servier, it is indicated for the symptomatic treatment of chronic stable angina pectoris in adult patients with normal sinus rhythm who are already controlled with the individual components taken at the same dose levels. Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and cardiac output, thereby decreasing myocardial oxygen demand. Ivabradine is a selective and specific inhibitor of the cardiac pacemaker If current, which controls the spontaneous diastolic depolarization in the sinoatrial node and regulates heart rate. By combining these two heart-rate-lowering agents with distinct mechanisms, Implicor provides an additive effect on heart rate reduction and anti-ischemic protection.
- Brand names
- Implicor
- Other names
- ivabradine/metoprololmetoprolol/ivabradineivabradine hydrochloride + metoprolol tartrate
02
Targets
ADRB1 (β1)HCN4 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4)
Beyond the preview
Go deeper on ivabradine + metoprolol (Servier).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivabradine + metoprolol (Servier).